Last updated on January 2020

Efficacy and Safety of Erenumab in Pediatric Subjects With Episodic Migraine


Brief description of study

This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to <12 years) and adolescents (12 to <18 years) with episodic migraine. The study hypothesis is that in pediatric subjects with episodic migraine, the combined erenumab dose group has a greater reduction from baseline to week 9 through week 12 (month 3) in monthly migraine days (MMDs) when compared with placebo in the double-blind treatment phase (DBTP).

Detailed Study Description

This study is a Phase 3, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to <12 years) and adolescents (12 to <18 years) with episodic migraine.

The trial consists of four phases: screening (up to 3 weeks of initial screening and a 4-week prospective baseline phase); the double-blind treatment phase (24 weeks) in which participants receive placebo or Erenumab dose 1, dose 2 or dose 3 (based on participant's body weight) via subcutaneous injection once a month; the optional dose level blinded extension phase (40 weeks), in which all participants are assigned to receive dose 1, dose 2 or dose 3 of Erenumab; and a 12 weeks safety follow-up phase (16 weeks after the last dose of investigational drug).

The study intends to enroll 456 participants (376 adolescents and up to 80 children).

Clinical Study Identifier: NCT03836040

Find a site near you

Start Over

Research Site

Colorado Springs, CO United States
  Connect »

Research Site

West Palm Beach, FL United States
  Connect »

Research Site

Indianapolis, IN United States
  Connect »

Research Site

Worcester, MA United States
  Connect »

Research Site

Ann Arbor, MI United States
  Connect »

Research Site

Kansas City, MO United States
  Connect »

Research Site

Amherst, NY United States
  Connect »

Research Site

Pittsburgh, PA United States
  Connect »

Research Site

Balassagyarmat, Hungary
  Connect »

Research Site

Miskolc, Hungary
  Connect »

Research Site

Basel, Switzerland
  Connect »

Research Site

Zollikon, Switzerland
  Connect »

Research Site

Cardiff, United Kingdom
  Connect »

Research Site

Baltimore, MD United States
  Connect »

Research Site

Budapest, Hungary
  Connect »

Research Site

Oxford, United Kingdom
  Connect »

Research Site

Aurora, CO United States
  Connect »

Research Site

Stamford, CT United States
  Connect »

Research Site

Washington, WA United States
  Connect »

Research Site

Miami, FL United States
  Connect »

Research Site

Plymouth, MN United States
  Connect »

Research Site

Saint Louis, MO United States
  Connect »

Research Site

New York, NY United States
  Connect »

Research Site

Cleveland, OH United States
  Connect »

Research Site

Brussel, Belgium
  Connect »

Research Site

Edmonton, AB Canada
  Connect »

Research Site

Debrecen, Hungary
  Connect »

Research Site

Bialystok, Poland
  Connect »

Research Site

Moscow, Russian Federation
  Connect »

Research Site

Novosibirsk, Russian Federation
  Connect »

Research Site

Saint Petersburg, Russian Federation
  Connect »

Research Site

Glasgow, United Kingdom
  Connect »

Research Site

Liverpool, United Kingdom
  Connect »

Research Site

Leipzig, Germany
  Connect »

Research Site

Cincinnati, OH United States
  Connect »

Research Site

Marshfield, WI United States
  Connect »

Research Site

Sendai-shi, Japan
  Connect »

Research Site

London, United Kingdom
  Connect »

Research Site

Philadelphia, PA United States
  Connect »